News

September 10, 2017

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
INDIANAPOLIS, Sept. 10, 2017 /PRNewswire/ -- At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed results from the global, randomized, double-blinded, placebo-controlled RANGE ...

September 9, 2017

IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine
INDIANAPOLIS, Sept. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase 3 SPARTAN study. Detailed...

September 8, 2017

IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
INDIANAPOLIS, Sept. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studies. Detailed results from a 12-month, open-label Phase 3 study will be p...

September 6, 2017

Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC)
INDIANAPOLIS, Sept. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the 18th Congress of the International Headache Society (IHC) taking place Sept. 7-10 in Vancouver. Lilly will highlight new, long-term data f...

August 30, 2017

Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
INDIANAPOLIS, Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. The resubmission package will ...

August 29, 2017

New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress
INDIANAPOLIS, Aug. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, September 8-12, 2017. Notably, results from Phase 3 studies of abemaciclib and ramucirumab have been selected for oral presentation ...

August 4, 2017

Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
INDIANAPOLIS, Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study. At two hours following the first dose, a greater percentage of patients treated with lasmidi...

July 25, 2017

Lilly and Incyte Provide Update on Baricitinib
INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), wil...

Showing 21-28 of 28 Page: 1 2  Previous 20